RE: Dilution30 Nov 2019 12:34
@strictlyinc - up to $25 million.....if beyond who pays ?
Avion has agreed to fund the full costs of the new optimised international Phase III trial for Lupuzor™ in lupus patients, based on an agreed level of expected costs up to $25 million. It is anticipated that this new Phase III trial will commence in 2020, following agreement of the trial design between Avion, ImmuPharma and the FDA. Following recruitment of patients (to include US, Europe and elsewhere), it is envisaged that this will be a 52-week trial. Both companies will jointly steer the clinical program.
@FLAVA
The price target mentioned by Halfbutt was in excess of 284p :-)
It never achieved that price even when IMM had less shares issued and when they had 100 % worldwide control of future revenues !
In the meantime the SP can go UP or down , this is IMM on AIM ....